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13Examination of the In Vivo Mechanisms of
Late Drug-Eluting Stent Thrombosis
Findings From Optical Coherence Tomography and Intravascular Ultrasound Imaging
Objectives This study investigated the role of uncovered stent struts on late stent thrombosis (LST)
after drug-eluting stent (DES) implantation with optical coherence tomography (OCT).
Background Autopsy studies have identiﬁed delayed healing and lack of endothelialization of DES
struts as the hallmarks of LST. DES strut coverage has not previously been examined in vivo in pa-
tients with LST.
Methods We studied 54 patients, including 18 with DES LST (median 615 days after implant) under-
going emergent percutaneous coronary interventions and 36 matched DES control subjects under-
going routine repeat OCT and intravascular ultrasound (IVUS) who did not experience LST for
3 years. Thrombus aspiration was performed during emergent percutaneous coronary intervention
before OCT and IVUS assessment.
Results By OCT, patients with LST—compared with control subjects—had a higher percentage of
ncovered (median [interquartile range]) (12.27 [5.50 to 23.33] vs. 4.14 [3.00 to 6.22], p  0.001) and
malapposed (4.60 [1.85 to 7.19] vs. 1.81 [0.00 to 2.99], p  0.001) struts. The mean neointimal thick-
ness was similar in the 2 groups (0.23  0.17 mm vs. 0.17  0.09 mm, p  0.28). By IVUS, stent ex-
pansion was comparable in the 2 groups, although positive remodeling was increased in patients
with LST (mean vessel cross-section area 19.4  5.8 mm2 vs. 15.1  4.6 mm2, p  0.003). Thrombus
spiration demonstrated neutrophils and eosinophils in most cases. By multivariable analysis, the
ength of segment with uncovered stent struts by OCT and the remodeling index by IVUS were in-
ependent predictors of LST.
onclusions In this in vivo case-controlled study, the presence of uncovered stent struts as assessed by
CT and positive vessel remodeling as imaged by IVUS were associated with LST after DES. (J Am Coll
ardiol Intv 2012;5:12–20) © 2012 by the American College of Cardiology Foundation
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MEnthusiasm for drug-eluting stents (DES) was initially fueled
by the ability of these devices to markedly reduce restenosis
(1,2). This initial fervor was tempered by a persistent 0.4% to
0.6% annual incidence of late stent thrombosis (LST) with
first-generation DES (3).
See page 21
Lack of healing and absence of endothelial cell coverage of
the stent struts have been strongly associated with DES
LST in human autopsy studies (4). To date, no in vivo
evidence has linked persistent lack of strut coverage to LST
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greater resolution, optical coherence tomography (OCT) is
superior to intravascular ultrasound (IVUS) imaging for
assessment of stent strut coverage and thrombus deposition
(7). Conversely, due to its greater tissue penetration, IVUS
provides complementary information on vessel remodeling
not available from OCT, which along with stent malappo-
sition has previously been associated with LST (8). There-
fore, we performed an in vivo mechanistic explorative study
with OCT and IVUS imaging in patients with and without
DES LST to determine the role of strut coverage, malap-
position, and vascular remodeling on late adverse events.
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14Methods
Study population and protocol. We implemented a protocol
in which immediate thrombus aspiration followed by OCT
and IVUS were performed during emergency percutaneous
coronary intervention (PCI) in patients presenting with
ST-segment elevation myocardial infarction (STEMI)
caused by DES LST. Only patients with definite LST as
defined by the Academic Research Consortium criteria (9)
in a native coronary artery were included. Patients with
occlusion at the coronary ostium or in vessels 4.0 mm in
diameter or in presence of excessive vessel tortuosity were
excluded, because these factors could interfere with OCT
image acquisition (10). Additional exclusion criteria were
patients resuscitated from cardiac
arrest or in cardiogenic shock. The
study complied with the Declara-
tion of Helsinki with regard to in-
vestigation of human subjects. The
Ethics Review Committee of Os-
pedali Riuniti di Bergamo approved
the protocol. Written informed
consent was obtained from all
patients.
Coronary angiography and blood
ﬂow restoration. After intracoro-
nary injection of 0.1 to 0.2 mg
nitroglycerin, coronary angiography
was performed to document the
presence of the thrombotic stent
occlusion. Thereafter, a standard
0.014-inch coronary guidewire was
passed through the occluded stent,
and multiple sequences of thrombus
aspiration were performed with an
aspiration catheter (Export Aspira-
tion System, Medtronic, Minneap-
olis, Minnesota) to restore Throm-
bolysis In Myocardial Infarction
flow grade 2 to 3, followed by OCT
and IVUS.
Histopathologic analysis. All thrombus aspirates were fixed
in 4% Neutral Buffered Formalin and sent to an Independent
Core Laboratory (CV Path Institute, Gaithersburg, Maryland)
for analysis. Each thrombus aspirate was measured in aggregate
and subsequently submitted for paraffin embedding. Sections
were cut at 5 m on a rotary microtome, mounted on slides,
nd stained with hematoxylin and eosin, Movat pentachrome,
nd Luna stain. The histological sections were examined by
ight microscopy for platelets, fibrin, red blood cells, plaque
onstituents, and inflammatory cells, including eosinophils. In
ddition, 5 high-power fields (40) demonstrating the great-
st severity of inflammation were selected for quantitative
Abbreviations
and Acronyms
CSA  cross-section area
DES  drug-eluting stent(s)
EEM  external elastic
membrane
IQR  interquartile range
ISA  incomplete stent
apposition
IVUS  intravascular
ultrasound
LST  late stent thrombosis
OCT  optical coherence
tomography
PCI  percutaneous
coronary intervention
PES  paclitaxel-eluting
stent(s)
SES  sirolimus-eluting
stent(s)
ST  stent thrombosis
STEMI  ST-segment
elevation myocardial
infarction
WBC  white blood cellnalysis. Data were recorded as total eosinophil number, totalhite blood cells (WBCs), and mean eosinophil fraction
xpressed as total eosinophil/total WBC.
OCT imaging and analysis. The OCT was performed with a
time domain commercially available System (M2CV OCT
Imaging system, LightLab Imaging, Inc., Westford, Mas-
sachusetts). The occlusive technique, with low-volume con-
tinuous flushing, was adopted to completely remove blood
from the artery (10). The OCT images were obtained with
motorized pullback at 1.0 mm/s. In case of multiple
pullbacks integrated information was obtained by using
fiducial points (i.e., stent edges, side branches). Quantitative
measurements of OCT images were performed offline
throughout the length of the stent, including distal and
proximal reference segments at every 1-mm interval, with a
dedicated automated contour-detection system (OCT sys-
tem software B.0.1, LightLab). All cross-sectional images
(frames) were screened for quality and excluded from
analysis if 25% of the image was out of the screen, if a
side-branch was present in the cross-section, or for inade-
quate image quality due to some artifacts (11). Qualitative
imaging assessment was performed in every frame to detect
the presence of intraluminal thrombus. Intracoronary
thrombus was identified as any abnormal mass protruding
beyond the stent struts into the lumen, with a sharp gap
with underlying neointima, signal backscattering, and var-
ious degrees of attenuation (12). White thrombi were
characterized by homogeneous signal rich and low-
backscattering attenuation. A ruptured plaque was defined
with validated criteria for plaque characterization (13).
Stent and lumen contours were semiautomatically delin-
eated, and tissue hyperplasia thickness, strut coverage, and
wall apposition were assessed for the entire circumference of
the vessel. Quantitative strut-level analysis was performed
on each individual strut along the entire target segment.
Struts were graded as covered (10-m tissue thickness) or
uncovered (10-m thickness), on the basis of the current
axial resolution of the available OCT system.
The number and percentage of completely apposed versus
unapposed and covered versus uncovered struts were deter-
mined. The proportion of frames with30% uncovered struts
as calculated. The maximum uncovered segment length was
efined as the number of consecutive frames at 1-mm intervals
ith uncovered struts. Strut malapposition was defined as
eparation of the stent strut surface from the inner vessel wall
y a distance greater than the width of the stent strut plus the
olymer coating, according to the different manufacture spec-
fications (14). The maximum malapposition length was de-
ned as the number of consecutive frames at 1-mm intervals
ith malapposed struts.
IVUS imaging and analysis. The IVUS was performed after
intracoronary administration of 0.1 to 0.2 mg of nitroglyc-
erin, with a commercially available iLab system with Atlan-
tis SR Pro 40-MHz catheters (Boston Scientific, Fremont,
California). Imaging was acquired with a motorized pull-
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15back at 0.5 mm/s to include the stent and at least 5-mm
segments proximal and distal to the stent. Quantitative
analysis was performed with standard methods and defini-
tions (15), via validated planimetry software (CAAS-QIVA
4.0, PieMedical Imaging, Maastricht, the Netherlands).
External elastic membrane (EEM), stent, lumen, and
malapposition cross-sectional areas (CSA) were measured at
1-mm axial increments throughout the length of the stent
and 5-mm segments proximally and distally to the stent.
Incomplete stent apposition (ISA) was defined as lack of
contact with the underlying vessel wall of at least 1 stent
strut, not overlying a side branch, and with evidence of
blood speckle behind the strut. In the segment with ISA,
the lumen contours were delineated within and outside the
stent strut boundaries. The ISA CSA was defined as the
fraction of the lumen area outside the stent. The minimum
stent CSA divided by the average of proximal and distal
reference lumen CSA ratio was calculated as a parameter of
stent expansion. Remodeling index was calculated, dividing
the maximum in-stent EEM CSA by the reference segment
EEM CSA. Marked positive remodeling was defined as a
remodeling index 1.1 (15).
Case-control analysis. Control cases were identified from a
arge sample of DES patients who underwent routine OCT
nd IVUS follow-up at 6 months in whom, with late
ollow-up to 3 years, ST never developed. The following
riteria were used for matching (all criteria had to be concom-
tantly met to qualify as control subject): 1) same stent type;
) comparable IVUS reference vessel EEM CSA (within 2
m2); 3) comparable IVUS reference lumen CSA (within2
m2); and 4) comparable IVUS stent diameter. Two control
subjects were identified for each LST case.
Statistical analysis. Categorical variables are presented as
umbers and frequencies and were compared by the chi-square
est or Fisher exact tests. Continuous variables are expressed as
ean  SD or median (first to third quartile) for nonpara-
etric data (p  0.05 at Shapiro–Wilk test) and were
ompared by the Wilcoxon rank-sum test, given the small
ample and potential presence of outliers. An exploratory
ultivariable logistic regression analysis picking only the 2
trongest univariate predictors was performed, given the small
umber of cases. All analyses were performed with SAS
tatistical software (version 9.1 or higher, SAS Institute, Inc.,
ary, North Carolina) and based throughout on nonpaired
ethods, given our preference for a more robust bivariate
nalysis, even if at the price of reduced statistical power.
esults
Patients. From June 2006 to April 2009, 547 primary PCIs
in STEMI patients were performed at our hospital. Definite
stent thrombosis (ST) occurred in 41 of 547 patients.
Among them, 23 patients were excluded from the study due
to ST: in bare-metal stent (n  6), acute/subacute (n  4),in cardiogenic shock or resuscitated patients (n  4), in
grafts (n 4), with unsuitable anatomy to OCT assessment
(n  5). Eighteen consecutive patients (with 35 DES) who
presented with STEMI due to definite LST with suitability
for OCT were included into the study. Six patients had
LST due to sirolimus-eluting stent (SES), 10 due to
paclitaxel-eluting stent (PES), 1 due to everolimus-eluting
stent, and 1 due to zotarolimus-eluting stent. One PES
patient had LST simultaneously in 2 different vessels. The
median time from DES implantation to LST was 615
(interquartile range [IQR]: 394 to 1,186) days (range 172 to
1,836 days). Fifteen patients (83%) had very late ST
(beyond 1 year after DES implantation). Stent thrombosis
occurred within 90 days of clopidogrel discontinuation in 4
cases (23%). A significant creatine kinase increase (2 the
upper value of the normal range) was confirmed in all
patients. All patients included into the study had IVUS and
OCT imaging performed after thrombus aspiration. No
major complications occurred because of the imaging as-
sessments, and all patients included into the study were
discharged alive from the hospital.
Baseline clinical, lesion, and stent features at the time of
implant in the patients with LST compared with the control
group are reported in Table 1. The patients with LST had
Table 1. Clinical and Procedural Characteristics at the Time
of Drug-Eluting Stent Implantation
ST
(n  18)
Control
(n  36) p Value
Age, yrs 61 (51–72) 67 (56–76) 0.28
Male 29 (80.6) 11 (61.1) 0.12
Hypertension 11 (61.1) 20 (55.6) 0.69
Hyperlipidemia 12 (66.7) 20 (55.6) 0.43
Diabetes 2 (11.1) 13 (36.1) 0.06
Prior myocardial infarction 6 (33.3) 9 (25.0) 0.51
Prior PCI 13 (72.2) 9 (25.0) 0.001
Prior CABG 0 (0) 1 (2.8) 0.67
Multivessel disease 11 (61.1) 20 (55.6) 0.69
Original stent implanted during an
acute coronary syndrome
14 (77.8) 15 (41.7) 0.01
Stents implanted/patient 1.83 0.78 2.31 0.52 0.03
Total stent length, mm 33 (24–48) 37 (32–44) 0.09
Stent diameter, mm 2.88 0.22 2.96 0.28 0.40
Stent overlap 13 (76.5) 34 (94.4) 0.06
Stent type
SES 6 (33.3) 12 (33.3) 1.00
PES 10 (55.5) 20 (55.6) 1.00
EES 1 (5.6) 2 (5.6) 1.00
ZES 1 (5.6) 2 (5.6) 1.00
Values are mean (range), n (%), or mean SD.
CABG coronary artery bypass grafting; EES everolimus-eluting stent(s); PCI percutane-
ous coronary intervention; PESpaclitaxel-eluting stent(s); SES sirolimus-eluting stent(s); ST
stent thrombosis; ZES zotarolimus-eluting stent(s).a higher incidence of prior PCI, slightly fewer stents
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16implanted, and were more likely to have the original stents
implanted during an acute coronary syndrome.
Histopathology of thrombus. A total of 16 thrombus spec-
imens were submitted for histopathology analysis; in 2
patients there was insufficient thrombus material for analy-
sis. The mean thrombus volume was 25.9  35.2 mm3. All
nalyzed thrombi demonstrated platelet- and fibrin-rich
reas (white thrombus) with varying numbers of red blood
ells associated with the platelet aggregates. No pure red
hrombi were present in our series; only 2 were mixed in
omposition. Most aspirates showed inflammatory cell in-
ltrates (median 264 [IQR: 167 to 400] WBCs/high power
eld) consisting predominantly of neutrophils admixed with
hronic inflammatory cells. Eosinophils identified by Luna
taining were present in most thrombi (ranging from 1% to
9% of WBCs) and were more commonly observed in SES
ompared with PES (eosinophil fraction 12.87 [IQR: 5.36
o 17.80] vs. 1.19 [IQR: 0.85 to 2.72], respectively, p 
.027). No significant correlation was found between his-
opathology components of thrombus, including high eo-
inophil fraction (20%), and all OCT findings.
OCT analysis. A complete visualization of all stents involved
ith LST, including proximal and distal reference segment,
as achieved in all patients. However, in 4 patients a second
ullback was needed to obtain the complete stent visualiza-
ion. A total of 484 cross-sections with 4,407 struts in 35
tents of the LST group and 1,088 cross-sections with 9,064
truts in 83 stents of the control group were analyzed. Of all
ecorded frames, 27% in the LST group and 25% in the
ontrol group were excluded from the analysis due to
ut-of-the-screen, sidebranch present, or presence of arti-
acts (p  0.13). Very few frames (3.6  2.2%) were
xcluded due to attenuation induced by residual red throm-
us. As shown in Table 2, the proportion of uncovered
truts/patient was significantly higher in the LST group
ompared with the control group (12.27 [IQR: 5.50 to
3.33] vs. 4.14 [IQR: 3.00 to 6.22], p  0.001). Most
atients with LST had sections with30% uncovered struts
13 of 18, 72%). In addition, patients with LST also had
onger stent segments with uncovered struts. Similarly, the
ate of malapposed struts/patient and the length of seg-
ents with malapposed struts were higher in the LST
roup. Three patients with LST (16.7%), however, did not
ave uncovered or malapposed struts but instead demon-
trated severe in-stent tissue hyperplasia (1 patient with
otarolimus-eluting stent) or a ruptured plaque within or
mmediately adjacent to the DES (PES) (in 2 of these
atients), as the likely mechanism of LST.
IVUS analysis. As shown in Table 3, the 2 groups were
well-matched for mean reference vessel size and lumen CSA
as well as stent expansion. However, the EEM at the stent
segment was markedly larger in patients with LST; positive
remodeling was present in 14 of 18 patients (77.8%) with
LST, compared with 11 of 36 (30.6%) of control subjects f(p  0.001). Among the LST patients with 30% uncov-
ered struts/section by OCT, 12 had positive remodeling by
IVUS (92%). The ISA CSA at the maximal malapposition site
was also significantly greater in the LST group than the control
group (4.1  2.3 mm2 vs. 1.2  1.5 mm2, p  0.001).
Exploratory multivariable analysis. Multivariable logistic re-
ression analysis, picking only the 2 strongest univariate
redictors of LST (namely maximum length of segments
ith uncovered struts at OCT, and remodeling index at
VUS), showed that both were concomitantly and indepen-
ently associated with LST (Table 4).
iscussion
The present study represents the first attempt for the in vivo
investigation of the role of uncovered struts in patients with
definite LST after DES. The main findings of this study are:
1) LST after DES was associated with OCT evidence of an
increased frequency and length of uncovered and malapposed
struts; 2) positive vessel remodeling was more frequently
observed in patients with compared with those without LST
and tend to be associated with sections with 30% uncovered
truts; and 3) LST after DES is not always related to lack of
tent coverage or vessel remodeling—other mechanisms might
n occasion be implicated, including in-stent or peri-stent
laque rupture and occlusive restenosis.
Histopathology obtained from human autopsy cases have
emonstrated delayed healing and incomplete endothelial
ell coverage as strong correlates of LST after DES implan-
ation (16). This pathological phenomenon has not been
eported in patients with bare-metal stent (14). Further-
ore, the presence of 30% uncovered struts/cross-section
as identified to be highly predictive of ST after DES
mplantation (17). Before the present report, however, these
bservations had never been confirmed in vivo.
In the current study, 14 of the 18 patients (78%) with
efinite LST exhibited uncovered struts (Fig. 1), and 13
atients (72%) had 30% uncovered struts/section. The fre-
uency of cross-sections with 30% uncovered struts was
6.7% in patients with LST, compared with 4.1% in the
atched control subjects from the present study and 2% at 2
ears in asymptomatic patients after SES implantation from a
rior study (18). Katoh et al. (19) reported that, in patients
ithout ST, the rate of uncovered SES struts decreases by 12
onths, but complete coverage is the exception. The current
tudy confirms that uncovered DES struts might persist for
everal years and might be a frequent finding for LST.
Long stents and multiple overlapping stents have been
reviously identified as predictors of LST after DES (20).
n the present study, despite similar stent length and
eointimal thickness in patients with and without LST,
hose with LST had a significantly higher rate and longer
egments of uncovered and malapposed struts. Of note, the
requency of uncovered struts reported at 6- to 12-month
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17follow-up in asymptomatic patients treated with first-
generation DES has varied from 0% to 8.4% (7,18,21),
significantly less than that we observed in patients with LST
in the present study. Lüscher et al. (22) have demonstrated
that DES implantation in lesions with abundant necrotic
core might result in delayed or absent healing and endothe-
lialization. This observation is consistent with the findings
of our study, where an acute coronary syndrome during the
Table 3. Intravascular Ultrasound Imaging Measurements
ST
(n  18)
Control Subjects
(n  36) p Value
Reference segment
Mean EEM CSA, mm2 13.6 3.9 13.7 3.5 0.50
Mean lumen CSA, mm2 6.9 1.7 6.9 1.8 0.96
Stent segment
Mean EEM, mm2 19.4 5.8 15.1 4.6 0.003
Remodeling index 1.24 (1.06–1.43) 0.99 (0.90–1.11) 0.001
Mean stent CSA, mm2 7.8 1.6 7.6 1.4 0.42
Minimal stent CSA, mm2 5.7 1.4 5.9 1.4 0.99
Minimal stent CSA  4 mm2 3 (16.7) 3 (8.3) 0.38
Stent expansion index 0.87 0.3 0.91 0.3 0.69
ISA 14 (77.8) 15 (41.7) 0.01
Maximal ISA CSA, mm2 4.11 2.3 1.16 1.5 0.001
Values are mean SD, mean (range), or n (%).
CSA cross sectional area; EEM external elastic membrane; ISA incomplete stent
Table 2. Optical Coherence Tomography Imaging Me
Cross-section level analysis
Analyzed cross-sections/patient, n
Struts analyzed/cross-section, n
Frequency of cross-sections with uncovered struts, %
Frequency of cross-sections with 30% uncovered struts
Maximum length of segments with uncovered struts, mm
Maximum length of segments with malapposed struts, m
Maximum malapposition distance, mm
Area of malapposition, mm2
Minimum stent area, mm2
Mean stent area, mm2
Mean neointimal area, mm2
Strut-level analysis
Number of struts analyzed/patient
Number of uncovered struts/patient
Frequency of uncovered struts/patient, %
Number of malapposed struts/patient
Frequency of malapposed struts/patient, %
Neointimal thickness of covered struts, mm
Values are mean SD or mean (range).
ST stent thrombosis.apposition; ST stent thrombosis.original stent implant was more frequently present in
patients with compared with those without LST.
The role of stent malapposition and vascular remodeling in
the pathogenesis of LST remains controversial. Cook et al. (8)
previously reported an increased incidence of stent malapposi-
tion and positive vessel remodeling as assessed by IVUS in
patients with compared with those without very late ST after
DES. In the present study, ISA was observed in 78% of
patients with LST (Fig. 2), and the maximal ISA CSA and
degree of positive remodeling were significantly greater in
patients with versus without LST. Localized strut hypersensi-
tivity with resultant positive remodeling after SES has been
associated with LST (23), whereas medial necrosis with arterial
dilation and excessive fibrin deposition was the underlying
cause after PES (24). We also found, consistent with the
findings of Cook et al. (24), eosinophilic-rich inflammatory
Table 4. Exploratory Multivariable Logistic Regression Analysis of
Late Stent Thrombosis
Variable OR (95% CI) p Value
Maximum length of segments with
uncovered struts at OCT, mm
2.45 (1.27–4.73) 0.007
Remodeling index at IVUS* 1.05 (1.01–1.11) 0.019
Only the 2 covariateswith strongest association at univariate analysiswere included in themodel,
given the limited number of cases. *Per 0.01-increase.
CI confidence interval; IVUS intravascular ultrasound; OCT optimal coherence
ments
ST
(n  18 Lesions;
4,407 Struts)
Control Subjects
(n  36 Lesions;
9,064 Struts) p Value
27 12 30 13 0.47
6.78 1.22 6.74 1.41 0.93
33.30 (11.82–53.00) 0.00 (0.00–7.80) 0.003
21.59 (0.00–43.70) 0.00 (0.00–6.09) 0.002
3.30 (1.35–4.13) 0.90 (0.00–1.55) 0.001
1.40 (0.68–1.93) 0.00 (0.00–0.00) 0.001
0.35 (0.00–0.75) 0.00 (0.00–0.62) 0.002
1.02 (0.00–1.92) 0.00 (0.00–0.32) 0.002
5.04 1.23 5.50 1.27 0.26
7.24 0.97 7.69 1.61 0.20
1.57 0.68 1.68 0.71 0.41
244 131 251 86 0.81
25.00 (8.25–52.25) 9.00 (4.25–14.00) 0.006
12.27 (5.50–23.33) 4.14 (3.00–6.22) 0.001
10.00 (2.25–21.75) 4.00 (0.00–7.00) 0.02
4.60 (1.85–7.19) 1.81 (0.00–2.99) 0.001
0.23 0.15 0.17 0.09 0.28asure
, %
mtomography; OR odds ratio.
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18infiltrates in several cases of LST (Fig. 2). These data are
consistent with the contention that late-acquired stent
malapposition and extensive vessel remodeling, rather than
causing LST, might only be a marker of underlying vascular
toxicity and inflammation, the likely proximate cause of ST.
Other mechanisms in addition to delayed healing and
vascular toxicity might occasionally be etiological in LST.
With intracoronary angioscopy, Higo et al. (25) found a 35%
increase in yellow neointima 10 months after DES implanta-
tion and hypothesized that the development of neoatheroscle-
rosis within the stented segment might serve as a possible
Figure 1. OCT Evidence of Uncovered Struts in DES Late Stent Thrombosis
Representative angiographic (A), intravascular ultrasound (IVUS) (B to D), and
patient with very late stent thrombosis at 1,836 days in a single sirolimus-elut
aspiration, uncovered struts are detected by OCT, with remaining intraluminal
DES  drug-eluting stent(s).
Figure 2. Vascular Toxicity as a Hallmark of DES Late Stent Thrombosis
Corresponding angiographic (A), IVUS long-view reconstruction (B), thrombus
with very late stent thrombosis at 1,103 days at the site of multiple overlappin
vessel remodeling was seen by IVUS at the site of uncovered struts with adhe
thrombus aspirate (C). Abbreviations as in Figure 1.substrate for LST. Pathological studies have also suggested
accelerated atherosclerosis and plaque progression after DES
placement (26). In the present study, 2 patients had OCT
evidence of a disrupted plaque with thrombus within or
immediately adjacent to a DES as the likely cause of LST,
without evidence of positive remodeling, stent malapposition,
or uncovered struts (Fig. 3). Finally, although usually consid-
ered a benign process, severe in-stent restenosis can present as
an acute coronary syndrome or myocardial infarction (27,28)
and was the likely cause of LST in at least 1 of our patients.
Thrombus has also been associated with severe SES restenosis,
l coherence tomography (OCT) (E to G) cross-sectional images from a
nt implanted in proximal left anterior descending artery. After thrombus
bus adherent to some strut. Positive remodeling was not observed by IVUS.
te histopathology (C), and OCT cross-sectional images (D, E) from a patient
limus-eluting stents in the mid left anterior descending artery. Expansive
rombi visualized by OCT. Large numbers of eosinophils were present in theoptica
ing ste
thromaspira
g siro
rent th
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19suggesting that neointimal hyperplasia developing after SES
might lack antithrombotic properties (29).
Study limitations. Although the 18 cases of LST in the
present report represent the largest such cohort acutely exam-
ined with OCT and IVUS, the number of LST cases is still
modest. There was no comparative bare-metal stent arm, so
the findings of the present study apply only to LST after DES.
At the time of the study, PES and SES were the most
frequently used stents in our institution; whether the vascular
responses and mechanisms of LST fundamentally differ with
next-generation DES, such as everolimus-eluting and
zotarolimus-eluting stents, cannot be answered from this
study. Furthermore, we compared OCT and IVUS data in the
LST group at a median of 615 days to imaging data acquired
at 180 to 270 days in the control group, the longest available
for appropriate matching. Ideally, the OCT control group
would have been performed at a time-point more closely
matching the occurrence of LST. Longer-term follow-up in
the control cohort might have demonstrated greater strut
coverage and/or more positive remodeling. Although both
OCT and IVUS were used in these patients, correlation
between IVUS and OCT findings was not attempted, due to
the limited number of cases and methodological differences in
analyses. The lack of OCT/IVUS imaging at index procedure
is an important limitation with regard to remodeling and late
acquired stent malapposition, especially in cases with stent
originally implanted in acute coronary syndrome patients,
where positive remodeling could be already present at baseline.
Figure 3. Neoatherosclerosis With Plaque Rupture in DES Late Stent Throm
Correspondent angiographic (A), thrombus aspirate histology (B), IVUS (C), an
multiple paclitaxel-eluting stents implanted in the mid left anterior descending
minal thrombus is visualized by OCT (D, E), with rare eosinophils from the thr
Abbreviations as in Figure 1.Whenever thrombus is present, a reliable assessment of strutcoverage is difficult. All analyzed aspirated thrombi were
platelet-rich, with low drops in OCT signal intensity. How-
ever, some shadowing was still present in OCT images with
residual thrombus, thus proportion and extent of uncovered
struts in the LST group is likely underestimated. Current
OCT cannot differentiate between neointimal and other tissue
types. Endothelial cell dimensions are below the resolution of
even OCT, and it is possible that some struts appearing bare were
covered by endothelium and thus misclassified. We cannot ex-
clude that thrombus aspiration might have partially removed the
material covering the struts. Our study failed to identify underex-
pansion as related to LST, most likely due to the use of expansion
feature in the matching process. Clinical variables that might
contribute to LST were not taken into account, because increasing
the number of matching factors beyond 4 would have made
matching altogether unfeasible. Finally, extensive multivariable
analyses were not possible, given the small sample, and only a
model combining the 2 strongest univariate predictors was ana-
lyzed with an exploratory scope.
Conclusions
The present in vivo study offers important insights into the
mechanisms underlying LST. Late stent thrombosis after
DES is associated with OCT evidence of uncovered struts
and IVUS evidence of positive remodeling consistent with
underlying vascular toxicity. Compared with asymptomatic
DES control subjects, those with LST had similar stent
(D, E) cross-sectional images of very late stent thrombosis (365 days) in
y in a patient with stable angina. A ruptured plaque with associated intralu-
s aspirate (B). Positive vessel remodeling was not present by IVUS (C).bosis
d OCT
arter
ombuCSA and expansion. Collectively these results support prior
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20human autopsy studies identifying delayed healing, lack of
endothelial cell coverage, and vascular toxicity as the hall-
marks of DES LST. Furthermore, the underlying mecha-
nisms of LST after DES are multifactorial, with etiologies
other than abnormal healing occasionally identified, includ-
ing neoatherosclerosis with new plaque rupture and throm-
bosis and occlusive in-stent restenosis
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